These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27566413)

  • 1. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
    BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
    J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
    Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
    BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
    J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
    Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A; Crosby L; Remick SC; Makkar V; Levitan N
    Lung Cancer; 2001 May; 32(2):155-62. PubMed ID: 11325486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
    Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
    Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang L; Huang R; Chu Z; Zhan Q
    J Thorac Oncol; 2010 Jun; 5(6):867-73. PubMed ID: 20521354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
    Artal-Cortés A; Gomez-Codina J; Gonzalez-Larriba JL; Barneto I; Carrato A; Isla D; Camps C; Garcia-Giron C; Font A; Meana A; Lomas M; Vadell C; Arrivi A; Alonso C; Maestu I; Campbell J; Rosell R
    Clin Lung Cancer; 2004 Nov; 6(3):175-83. PubMed ID: 15555219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
    J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.